Anavex 2-73 Trial for Early Alzheimer’s Expanded to Canada, UK

Anavex 2-73 Trial for Early Alzheimer’s Expanded to Canada, UK
Anavex Life Sciences will expand its Phase 2b/3 clinical trial testing the efficacy and safety of Anavex 2-73 (blarcamesine) for the treatment of early Alzheimer’s disease into Canada and the United Kingdom (U.K.) following the go-ahead from Health Canada and the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA).  The clinical trial, dubbed Anavex 2-73-AD-004 (NCT03790709), is a placebo-controlled study currently underway in Australia, with more than 50% of the 450 patients enrolled. Participants are age 60 to 85 with mild cognitive impairment or early stage mild dementia due to Alzheimer’s. (More information about recruitment is available here.) “We are excited to receive the regulatory approvals for this Phase 2b/3 study for patients seeking treatment for Alzheimer’s disease,” said Christopher Missling, PhD, president and CEO of Anavex, in a
Subscribe or to access all post and page content.